TruAlt Bioenergy fined ₹4.55 lakh each by NSE, BSE for board norm breach
- TruAlt Bioenergy fined ₹4.55 lakh each by NSE and BSE
- Penalties relate to alleged non-compliance with board composition norms
- Violation involves delayed appointment of a woman independent director
- Company states financial impact is limited to the fine amounts
*this image is generated using AI for illustrative purposes only.
TruAlt Bioenergy has been fined ₹4.55 lakh each by the National Stock Exchange and BSE for alleged non-compliance with board composition requirements. The penalties were imposed on August 25, 2026, for delayed appointment of a woman independent director.
The company disclosed the penalties on August 26, 2026, under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The exchanges cited violations of Regulation 17(1) regarding the composition of the Board.
Penalty Details
The stock exchanges levied monetary fines for the alleged delayed compliance with regulatory norms. The specific details of the action are as follows:
| Authority | Fine Amount | Reason |
|---|---|---|
| National Stock Exchange | ₹4.55 lakh | Non-compliance with Regulation 17(1) |
| BSE Limited | ₹4.55 lakh | Failure to appoint woman independent director |
The fines are payable plus applicable GST. The company stated that the financial impact is limited to these imposed amounts.
Regulatory Compliance
TruAlt Bioenergy is examining the notices received from the exchanges. The company intends to take appropriate steps in the matter. The issue will be placed before the Board of Directors in the ensuing meeting.
The disclosure was made pursuant to Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
Historical Stock Returns for Trualt Bioenergy
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.72% | -3.72% | +0.65% | +13.02% | 0.0% | 0.0% |
Will TruAlt Bioenergy face additional regulatory scrutiny or higher penalties if similar governance lapses are detected in future compliance audits?
How might this penalty impact institutional investor confidence and the company's stock valuation in the short to medium term?
Does the company have a revised timeline for appointing the woman independent director, and what internal governance reforms are being implemented to prevent recurrence?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
